Novartis announced that the U.S. Food and Drug Administration (FDA) approved Leqvio (inclisiran) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-Cholesterol. Inclisiran is the first FDA-approved small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol.
Thank you for participating in the 21 Day Challenge. Below please find your opportunity to reflect on today's activity. Note: Chapter and Reflection are the only mandatory fields, though the NLA hopes to collect participant demographic data for improvement of DEI within our organization.
This page was last updated: Feb 20, 2022
The National Lipid Association would like to extend its congratulations to all of our Fellows of the NLA, current and past, honored at the 2023 National Lipid Association Honors & Awards Ceremony earlier this month:
Cindy L. Bredefeld, DO, FNLA
Jaime Burkle, MD, FNLS
Joette Hughes, MSN, CRNP, CLS, FNLA
Sabyasachi Sen, MD, FNLA
The U.S. Food and Drug Administration released a Drug Safety Communication on July 20, 2021, concerning the removal of the strongest warning against using statins during pregnancy. The warning states that statins should never be used in any patients during pregnancy.
* Indicates required question. Please be as exact as possible. All questions must be answered in order to be eligible.
This page was last updated: Sep 12, 2025
It has been challenging to start my term as Midwest Lipid Association President during the COVID-19 pandemic. Our first MWLA Board meeting was not held until the Fall of 2020. However, despite the circumstances in which we find ourselves, I am delighted to report that the MWLA has been moving forward on our agenda and we have been busy!
President, Midwest Lipid Association
Scientist, Robarts Research Institute
Professor, Department of Physiology & Pharmacology
Schulich School of Medicine & Dentistry
London, ON
The members of the Pacific chapter of the National Lipid Association were thrilled to share in the sponsorship duties for this edition of LipidSpin with our Midwest colleagues.
President, Pacific Lipid Association
Director, Clinical Associate Professor
Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID
Hyperlipidemia is a significant causal factor in the development of atherosclerotic cardiovascular disease, the leading cause of death in developed countries.(1) The burden of atherosclerotic cardiovascular disease (ASCVD) has decreased over the past several decades, with approximately half the decline attributable to medical therapy (2) directly correlating with absolute LDL-C reduction.(3) This improvement has been primarily attributed to the increased utilization of statins, which ha
Internal Medicine Resident
Hennepin Healthcare
Minneapolis, MN
Cardiac Rehabilitation Program Director
Department of Cardiology, South Sacramento Kaiser
Permanente
Permanente Medicine, The Permanente Medical Group
Sacramento, CA
Diplomate, American Board of Clinical Lipidology
Despite substantial improvements in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of death worldwide.(1,2) Continued prevalence of ASCVD is attributable to behaviors that impact control of known risk factors such as dyslipidemia, hypertension, pre-diabetes, diabetes, obesity, and metabolic syndrome.
Clinical Nutritionist
University of Wisconsin Hospital and Clinics
Madison, WI
Assistant Professor of Medicine
Department of Medicine
Division of Cardiology
University of Illinois at Chicago
Chicago, IL
The following case involves a 58-yearold gentleman with a history of complex cardiovascular disease and several cardiometabolic risk factors as listed below.
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Cardiology Fellow
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
.jpg)
.png)
